Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Carbetocin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OXTR known ✓ | P30559 | 16/20 | 0.94 |
| ▸ | AVPR1A | P37288 | 11/20 | 0.94 |
| ▸ | AVPR2 | P30518 | 10/20 | 0.94 |
| ▸ | AVPR1B | P47901 | 6/20 | 0.94 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Carbetocin SCHEMBL23118167 | 0.97 | OXTR (0.90) | OXTRAVPR1AAVPR2AVPR1B | |
| Carbetocin SCHEMBL39224 | 0.97 | OXTR (1.00) | OXTRAVPR1AAVPR2AVPR1B | |
| Carbetocin SCHEMBL28528620 | 0.97 | OXTR (1.00) | OXTRAVPR1AAVPR2AVPR1B | |
| Carbetocin SCHEMBL19712191 | 0.97 | OXTR (1.00) | OXTRAVPR1AAVPR2AVPR1B | |
| Carbetocin SCHEMBL23118157 | 0.97 | OXTR (1.00) | OXTRAVPR1AAVPR2AVPR1B | |
| Carbetocin SCHEMBL23118146 | 0.96 | OXTR (0.94) | OXTRAVPR1AAVPR2AVPR1B | |
| Carbetocin SCHEMBL23118135 | 0.96 | OXTR (0.94) | OXTRAVPR1AAVPR2AVPR1B | |
| Carbetocin SCHEMBL23118152 | 0.96 | OXTR (0.87) | OXTRAVPR1AAVPR2AVPR1B | |
| Carbetocin SCHEMBL23118144 | 0.96 | OXTR (0.93) | OXTRAVPR1AAVPR2AVPR1B | |
| Carbetocin SCHEMBL19745049 | 0.96 | OXTR (0.97) | OXTRAVPR1AAVPR2AVPR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210087233-A1 | DEUTERATED FORMS OF CARBETOCIN AND ANALOGS THEREOF | BRYANT CHRISTOPHER (US) | 2021-03-25 | — | — | US | claimed |
| US-20210087233-A1 | DEUTERATED FORMS OF CARBETOCIN AND ANALOGS THEREOF | BRYANT CHRISTOPHER (US) | 2021-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210087233-A1 | DEUTERATED FORMS OF CARBETOCIN AND ANALOGS THEREOF | OXTR, CRH, MC2R | OXTR 1/4885AVPR1A 14/4885AVPR2 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.